Dr Duncan Hewett

Grant-Funded Researcher B

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

My Research
Publications
Supervision
Contact

Dr Duncan Hewett is a senior postdoctoral scientist in the Myeloma Research Group of Dr Kate Vandyke. He is located within the Cancer Theme at SAHMRI on North Terrace. Multiple Myeloma is a largely incurable haematological cancer caused by the clonal expansion of differentiated B cells called plasma cells. His research focuses on using cell-based and mouse-based models of multiple myeloma to more fully understand the roles that mutated or dysregulated genes play in cancer initiation and progression, and to test the pre-clinical efficacy of novel anti-myeloma therapeutics.

Current projects include: (a) in vivo genetic screens using CRISPR-Cas9 to identify mechanisms of tumour cell survival ; (b) identifying molecular and cellular factors that enable to cancer cells to evade immune surveillance; (c) testing novel therapies directed towards neutralization of cancer-growth promoting bone marrow stromal factors; (d) development of lenalidomide-responsive and iberdomide-responsive in vivo models of myeloma

Opportunites exist in Semester 1 2024 for Honours and HDR projects for new students across many of the above projects. Please contact me via email to discuss further and/or arrange a visit to our laboratory located within the Precision Medicine Theme in the South Australian Health and Medical Research Institute (SAHMRI).

Project 1

Title: Discovery of novel essential genes for multiple myeloma cancer growth

Description: Using specific gene knockout in multiple myeloma cell lines grown in vivo in mice to study the mechanisms on which these cancer cells are dependent for their survival. Use of small molecule antagonists to determine putative clinical translation of these novel target proteins.

Projects Available For: Honours or HDR

Location: SAHMRI North Terrace

Research Project Start: Semester 1 2024

Special Requirements: none

Project 2

Title: Reprogramming tumour associated macrophages to treat multiple myeloma

Description: Combining novel compounds and immunomodulatory IMiD drugs in cell and animal based models of multiple myeloma to try and reprogram macrophages to stimulate the immune-mediated killing of cancer cells.

Projects Available For: Honours or HDR

Location: SAHMRI North Terrace

Research Project Start: Semester 1 2024

Special Requirements: none

Journals

Year	Citation
2020	Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.. PLoS One, 15(1), e0228408. DOI WoS2 Europe PMC1
2020	Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108. DOI Scopus16 WoS15 Europe PMC10
2020	Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 15(1), e0228423. DOI Scopus2
2020	Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353. DOI Scopus2 Europe PMC3
2020	Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20. DOI Scopus3 WoS3 Europe PMC1
2020	Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development.. FASEB Bioadv, 2(9), 554-572. DOI Scopus1 Europe PMC1
2020	Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187. DOI Scopus7 WoS6 Europe PMC5
2019	Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., . . . Croucher, P. I. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43. DOI Scopus70 WoS69 Europe PMC56
2019	Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787. DOI Scopus42 WoS39 Europe PMC32
2019	Dutta, A., Fink, J., Grady, J., Morgan, G., Mullighan, C., To, L., . . . Zannettino, A. (2019). Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 33(2), 457-468. DOI Scopus70 WoS69 Europe PMC56
2018	Dutta, A. K., Hewett, D. R., Fink, J. L., & Zannettino, A. C. W. (2018). Using genomics to better define high-risk MGUS/SMM patients. Oncotarget, 9(93), 36549-36550. DOI Scopus2 Europe PMC1
2017	Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616. DOI Scopus34 WoS33 Europe PMC23
2017	Dutta, A., Hewett, D., Fink, J., Grady, J., & Zannettino, A. (2017). Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 178(2), 196-208. DOI Scopus14 WoS14 Europe PMC11
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus37 WoS36 Europe PMC25
2017	Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981. DOI Scopus13 WoS12 Europe PMC10
2015	Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38. DOI Scopus25 WoS26 Europe PMC20
2015	Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399. DOI Scopus23 WoS21 Europe PMC20
2015	Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16. DOI Scopus24 WoS24 Europe PMC19
2014	Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585. DOI Scopus31 WoS31 Europe PMC27
2010	Melo, J. V., & Hewett, D. R. (2010). Wrapping BCR-ABL: It's in the bag. Blood, 116(18), 3382-3383. DOI Scopus2
2010	Barlow, J., Drynan, L., Hewett, D., Holmes, L., Lorenzo-Abalde, S., Lane, A., . . . McKenzie, A. (2010). A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nature Medicine, 16(1), 59-66. DOI Scopus284 Europe PMC226
2008	Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888. DOI Scopus159 WoS144 Europe PMC117
2006	Fallon, P. G., Ballantyne, S. J., Mangan, N. E., Barlow, J. L., Dasvarma, A., Hewett, D. R., . . . McKenzie, A. N. J. (2006). Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. Journal of Experimental Medicine, 203(4), 1105-1116. DOI Scopus590 Europe PMC460
2005	Hewett, D. R., Simons, A. L., Mangan, N. E., Jolin, H. E., Green, S. M., Fallon, P. G., & McKenzie, A. N. J. (2005). Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Human Molecular Genetics, 14(2), 335-346. DOI Scopus77 Europe PMC51
2002	Hewett, D., Samuelsson, L., Polding, J., Enlund, F., Smart, D., Cantone, K., . . . Purvis, I. (2002). Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics, 79(3), 305-314. DOI Scopus96 Europe PMC63
2002	Maniatis, N., Collins, A., Xu, C. F., McCarthy, L. C., Hewett, D. R., Tapper, W., . . . Morton, N. E. (2002). The first linkage disequilibrium (LD) maps: Delineation of hot and cold blocks by diplotype analysis. Proceedings of the National Academy of Sciences of the United States of America, 99(4), 2228-2233. DOI Scopus148 Europe PMC114
2001	McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics, 78(3), 135-149. DOI Scopus115 Europe PMC84
2001	McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Erratum: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine (Genomics (2001) 78 (135-149)). Genomics, 79(2), 271. DOI
1998	Hewett, D., Handt, O., Hobson, L., Mangelsdorf, M., Eyre, H., Baker, E., . . . Richards, R. (1998). FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Molecular Cell, 1(6), 773-781. DOI Scopus80 WoS75 Europe PMC53
1997	Yu, S., Mangelsdorf, M., Hewett, D., Hobson, L., Baker, E., Eyre, H., . . . Richards, R. (1997). Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell, 88(3), 367-374. DOI Scopus174 WoS160 Europe PMC109
1997	Horwitz, M., Benson, K., Li, F. Q., Wolff, J., Leppert, M., Hobson, L., . . . Raskind, W. (1997). Genetics heterogeneity in familial acute myelogenous leukemia: Evidence for a second locus at chromosome 16q21-23.2. American Journal of Human Genetics, 61(4), 873-881. DOI Scopus39 WoS34 Europe PMC26

Conference Papers

Year	Citation
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.

Conference Items

Year	Citation
2019	Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI

Datasets

Year Citation
- Dutta, A., Zannettino, A., Hewett, D., & l.fink@uq.edu.au. (n.d.). ZANNETTINO_EGA DAA_EGAS00001002850.doc.
DOI

Year	Citation
-	Dutta, A., Zannettino, A., Hewett, D., & l.fink@uq.edu.au. (n.d.). ZANNETTINO_EGA DAA_EGAS00001002850.doc. DOI

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2021	Principal Supervisor	Investigating the role of Gremlin1 in driving multiple myeloma cancer development and progression	Doctor of Philosophy	Doctorate	Full Time	Miss Emma Anna-Jane Cheney
2020	Principal Supervisor	Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells	Doctor of Philosophy	Doctorate	Full Time	Miss Hayley Bridget Parkinson

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2019 - 2023	Co-Supervisor	The TAM receptor family in multiple myeloma	Doctor of Philosophy	Doctorate	Full Time	Miss Justine Rachel Clark
2017 - 2020	Co-Supervisor	CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance	Doctor of Philosophy	Doctorate	Full Time	Miss Mara Natasha Zeissig
2015 - 2019	Co-Supervisor	The Role of SAMSN1 in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Ms Natasha Friend
2015 - 2020	Co-Supervisor	The Role of Gremlin1 in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Mrs Kimberley Claire Clark
2014 - 2018	Co-Supervisor	A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Ankit Kumar Dutta
2009 - 2013	Co-Supervisor	Regulation of BCR-ABL expression via its 3'untranslated region	Doctor of Philosophy	Doctorate	Full Time	Mr Bradley Chereda

Position: Grant-Funded Researcher B
Phone: 81284694
Email: duncan.hewett@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI, floor 5 South
Org Unit: Medical Sciences

Dr Duncan Hewett

Journals

Conference Papers

Conference Items

Datasets

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Connect With Me

External Profiles